Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 2Phase 1 2

Status

Completed 4Terminated 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 87Gemcitabine 81Carboplatin 63fludarabine 62Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 50Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 34Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26atezolizumab 25Pemetrexed 25Oxaliplatin 24Capecitabine 24fludarabine phosphate 23Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Terminated × 1-dodecylpyridoxal × Clear all
NCT04244552 2023-12-29

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Atreca, Inc.

Phase 1 Terminated
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01329549 2014-11-27

Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Boehringer Ingelheim

Phase 1 Terminated
2 enrolled 5 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡